Peggy Scherle
2020
In 2020, Peggy Scherle earned a total compensation of $2.7M as Chief Scientific Officer at Prelude Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $171,552 |
|---|---|
| Option Awards | $2,170,824 |
| Salary | $347,865 |
| Total | $2,690,241 |
Scherle received $2.2M in option awards, accounting for 81% of the total pay in 2020.
Scherle also received $171.6K in non-equity incentive plan and $347.9K in salary.
Rankings
In 2020, Peggy Scherle's compensation ranked 4,271st out of 13,090 executives tracked by ExecPay. In other words, Scherle earned more than 67.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,271 out of 13,090 | 67th |
Division Manufacturing | 1,726 out of 5,621 | 69th |
Major group Chemicals And Allied Products | 670 out of 2,254 | 70th |
Industry group Drugs | 573 out of 1,954 | 71st |
Industry Pharmaceutical Preparations | 437 out of 1,459 | 70th |
Source: SEC filing on April 29, 2022.
Scherle's colleagues
We found three more compensation records of executives who worked with Peggy Scherle at Prelude Therapeutics in 2020.